Background
As antiretroviral treatment (ART) programmes mature, data on drug utilization and costs are needed to assess durability of treatments and inform programme planning.
Methods
Children initiating ART were followed in an observational cohort in Thailand. Treatment histories from 1999–2009 were reviewed. Treatment changes were categorized as: drug substitution (within class), switch across drug class (non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and protease-inhibitor (PI), and to salvage therapy (dual PI or PI and NNRTI). Antiretroviral drug costs were calculated in six-month cycles (US$ 2009 prices). Predictors of high drug cost including characteristics at start of ART (baseline), initial regimen, treatment change and duration on ART were assessed using mixed-effects regression models.
Results
507 children initiated ART with a median 54 (IQR, 36–72) months of follow-up. Fifty-two percent had a drug substitution, 21% switched across class and 2% to salvage therapy. When allowing for drug substitution, 78% remained on their initial regimen. Mean drug cost increased from $251 to $428 per child per year in the first and fifth year of therapy, respectively. PI-based and salvage regimens accounted for 16% and 2% of treatments prescribed and 33% and 5% of total costs, respectively. Predictors of high cost include: baseline age ≥8 years, non nevirapine-based initial regimen; switch across drug class and to salvage regimen (p<0.005).
Conclusion
At 5 years, 21% of children switched across drug class and 2% received salvage therapy. The mean drug cost increased by 70%. Access to affordable second and third-line drugs is essential for the sustainability of treatment programmes.